UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $100 from $75 and keeps a Buy rating on the shares. Oruka reported stronger than expected data for PASI-100, meeting the firm’s “blue-sky” upside scenario, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics announces $500M common stock, warrants offering
- Oruka Therapeutics price target raised to $131 from $71 at Clear Street
- Morning News Wrap-Up, 4/27/26: Today’s Biggest Stock Market Stories!
- Oruka Therapeutics rises 19.0%
- Oruka Therapeutics price target raised to $160 from $78 at Barclays